About Clearmind Medicine Inc. - Common Shares (CMND)
Clearmind Medicine Inc is a biotechnology company focused on developing innovative therapeutics aimed at treating mental health disorders. The company leverages its expertise in psychedelic research to create novel compounds that can address conditions such as depression, anxiety, and addiction. By combining advanced scientific approaches with an emphasis on safety and efficacy, Clearmind aims to revolutionize the way mental health issues are treated, ultimately improving patient outcomes and quality of life. Their commitment to rigorous clinical trials and research positions them at the forefront of the emerging field of psychedelic medicine. Read More
Vancouver, Canada, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the Company’s clinical trial, of which the first cohort treatment was successfully completed.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Shares of Clearmind Medicine Inc. (NASDAQ: CMND) are falling Friday after the clinical-stage biotech company shared a key update about its stock listing.
The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected by receipt of the Notification Letter
